Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree about the vaccine, but until the system is changed it's what Missling has to work with. Safety and reasonably proved effective isn't good enough for the system we have. Get yourself elected or get on the FDA and maybe you can change the system from the inside.
Missling doesn't give a crap about AF, nor should he.
No one. Not Missling, not AVXL supporters on Twitter, not anyone anywhere should engage with that guy. It's an old adage (cause I'm old), but you never argue with someone who has more printers ink than you. I know that exact analogy doesn't apply here and the point of a platform like Twitter is to give everyone equal amounts of ink, but you and I both know that in the end AF wins a long protracted Twitter war.
AVXL wins when Missling can produce irrefutable data that even AF and his ilk have to say WOW they actually did it.
Until then F that guy. Ignore him.
These price targets make me laugh. I know there's some intellectual rigor, spreadsheet building, etc., but ultimately AVXL is either worthless OR it's priceless.
In no scenario is it worth $40.00.
Did you say the same thing to the poster I responded to who said Missling has seen the data? If not, why not?
Correct. Missling has seen the AD results. Because the results aren't what he hoped he will have to contextualize them for investors so that they look better than they actually are. Contextualize is just another way to say cherry picked.
The stock definitely is red tomorrow. Whenever there's a press release about mice, precision medicine and now this the stock goes down. Heck even when there's a PR about trial success the stock goes down.
Only when Missling releases AD data showing the drugged group's MMSE increases the maximum number of points and at the same time the FDA and all worldwide entities approve the drug for immediate prescription will the stock go up $5.00. Even then some will say the drug doesn't work, the data is cherry picked and the stock will finish in the red.
Correct, it's called man-spanning.
BTW - does anyone know what Missling means by "First"?
"THE" first meaning no one else has done this?
Does he mean first by Anavex, but there are others?
Does he the first of many such analyses by Anavex or others?
When investors have to assume or guess what is meant that's a problem that is self inflicted. Which as everyone knows is status quo for this guy.
So are broken watches twice a day.
Precision medicine is a RED HERRING
Contextualize means that the results don't speak for themselves.
In others words, here are the results, but you're too dumb to interpret them so look over for the context and let us explain it to you hoping you don't notice the problems with the data.
God, these guys have the worst copy writers on the planet.
5 of 6 stocks on the list he was 100% correct about. Anavex could make it 6/6.
Unless and until Missling can stand at the podium at one of these conferences and tell the world all dots are connected and we got this nothing matters.....especially a virtual poster on a Sunday.
Missling should be in San Diego anyway for meetings with potential partners and investors. Heck, go for weather if nothing else.
Five of the six tickers listed by Skrelli are either worthless or valued at less than $30 million. Seems like an 83% hit rate is pretty good to me. I know I'd take it every day.
So far AVXL is the star of the list, but will drop 90% with any sort of failure and Skrelli will have been correct in his prediction for all six listed in the picture.
The Federalist perspective on AD science corruption. Some is a rehash of the article in another publication last week. Also, if you listen to Podcasts the latest Federalist podcast has the author on today. Very much worth a listen as well..
https://thefederalist.com/2022/07/28/inside-the-corrupt-world-of-alzheimers-science-and-what-its-failure-means-for-all-settled-science/
Mostly preaching to many of this choir who have been singing a tune like this for years now, but still good to hear others as well.
Just saw this somewhere else.....in the long run this is really good for Anavex. In the short run the sheep may assume all companies researching AD are falsifying data.
As if message boards are reliable.
Missling committed to PR last patient last visit for AD. Believe that or not with a link. Up to you.
He's made lots of commitments and didn't follow through. No one should be surprised at this point.
Lots of posts over on $AVXL twitter saying yes the data is at best inconclusive and at worst outright fraud. At this point with these guys - MIssling - I'm starting to entertain the possibility of while not fraudulent data, but cherry picked so they can keep going.
Seems like more Anavex bears are coming out of the shadows over on Twitter spewing FUD. Even Adam F. lobbed in a grenade responding to a tweet from an Anavex bull.
Missling needs to find out when Adam F. is on vacation - preferably out of the country with no internet access - and release all the data he has then.
Twitter has a new post at $AVXL:
FAKE RED HERRING
Just shows how week anavex is when a small time discredited former science hack with a PhD from LSU can bring this stock down 20%. He was probably fired from Merck (per his L.I. page) and had to set up his own company to pay his bills.
Just wait until Adam F. reviews the next set of results at Twitter. We're so screwed with this management team.
So all biotechs are sold after Roe is overturned? The drop in AVXL, XBI and many others happened within a minute or two of the ruling. Makes senses a CNS drug company is sold off after an abortion ruling. The biotech market is such a joke.
Berenberg analyst Caroline Palomeque initiates coverage on Anavex Life Sciences (NASDAQ: AVXL) with a Buy rating. Couldn't see price target. Behind pay wall.
Yea and on tiny trades. Day trader morons selling market orders. No volume, but the stock drops 10 cents a pop.
Let's hear it for the predictive ability of mouse data!!! ATHA late stage program in AD fails to meet primary and secondary endpoints.
The additional details were sent as private invitations to the people/firms Missling wants to attend. Not everything has to be a PR and definitely not everything has to include an invitation to retail shareholders. I think Missling has demonstrated his disdain for retail so no one should be surprised.
Missling has either canceled the R & D day OR the attendees are by invitation only.
If it's canceled we'll get a PR after the market closes tonight.
So you write your posts as a public service? Thanks.
That's just it...no prospective CEO will jump at the chance to take the helm until the job is de-risked. That's also why the stock is at $7.50 - because no investors are willing to take the risk of losing all their investment. Just like new CEO isn't willing to take the risk of losing their job. Especially with a recession on the way.
You didn't address my point that Missling is likely the best CEO Anavex can attract.. Anyone "reputable" won't join Anavex right now.
Oh, and you've been killing Anavex for 7 years now. You've now just turned to Missling, but for 7 years day after day you've more or less called the company garbage. You may own some shares, but as you've said before it's a lottery ticket with no real belief in the science.
You ever think about the fact that Missling is the best they can do for CEO?
Any potential CEO worth anything would conclude as you have that this company has minimal potential and it's only a matter of time before the drug fails.
You basically say that the company can snap its fingers and hire a new CEO and BOD. You and I both know it doesn't work that way.
R & D day canceled do to lack of interest.
I don't think that will be PR 'd.
That's why Missling will need to conduct another AD trial in the U.S. with 1500 patients taking another 3 to 4 years before readout. Unless the data is so compelling which I don't think it is or the current trial would have been halted so that those participants on placebo could receive the real drug.
I suppose an approval just in Australia could lead to revenue there which would obviously be good.
The valuation at a $5 stock price has nearly doubled since 2017 since the outstanding shares have nearly doubled so some level of success has been priced in even at these levels.
Rubbish. Vickers is asking for up to 5 extensions. Only reason to do this is if you are figuring out how to get out of the deal.
As I predicted Vickers is trying to get out of the SPAC deal.
I don't know if they can legally, but for the moment they're delaying. Supposedly the deal will close by Q3 which to me means by 6/30. I guess we'll see.
Is there a basis for saying "greedy bastard"? Seriously. I've only read posters complaining about Missling's compensation without providing any context for the complaint? Greedy compared to other CEOs of comparable firms would work. Is the average comp. of a pre revenue, less than $1 billion market cap public company significantly less than $700K + 20% bonus + 500K options? I don't know the answer, but then again I don't complain about Missling's comp. Many other things, but not comp.
All that said, I do agree the milestones on his latest options are garbage.
Probably doesn't mean anything, but if you go to indeed.com and search for Sorrento's job postings you'll find many pages of jobs posted in the last week. Several of which are finance jobs. The VP Finance is in my linked in network and he posted an opening there that I saw. At the very least with this one data point Sorrento is operating like a going concern.
What page is PDD OLE data...positive on? I can't find it at first glance.
I agree that the right comps. are required. Big Pharma is not a comp. to Anavex.
I don't know what bank is, but $700K in NYC is NOT bank.